HomeBBIO • NASDAQ
BridgeBio Pharma Inc
Follow
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 211.12M | 11,461.88% |
Operating expense | 206.78M | 66.80% |
Net income | -35.22M | 74.87% |
Net profit margin | -16.68 | 99.78% |
Earnings per share | -0.12 | 86.05% |
EBITDA | 5.34M | 104.41% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 519.69M | 5.78% |
Total assets | 849.33M | 35.75% |
Total liabilities | 1.89B | 2.55% |
Total equity | -1.04B | — |
Shares outstanding | 187.13M | — |
Price to book | -5.53 | — |
Return on assets | 1.34% | — |
Return on capital | 1.72% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -35.22M | 74.87% |
Cash from operations | -219.54M | -52.12% |
Cash from investing | 22.75M | 85.01% |
Cash from financing | 279.55M | 86.06% |
Net change in cash | 82.76M | 354.12% |
Free cash flow | -207.18M | -181.76% |
Previous close
$31.04
Day range
$29.59 - $30.77
Year range
$12.75 - $44.32
Market cap
5.63B USD
Avg Volume
1.49M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
CEO
Founded
2015
Headquarters
Website
Employees
553